Table 2.
Patient characteristics per strata of non-specific ST-T abnormalities
| Non-specific ST-T abnormalities in SLE (n=50) |
Non-specific ST-T abnormalities in RA (n=139) |
|||||
|---|---|---|---|---|---|---|
| Present (n=22) | Absent (n=28) | p Value | Present (n=24) | Absent (n=115) | p Value | |
| Age, years | 41.0±15 | 32.8±9 | 0.03 | 61±8 | 59±8 | 0.29 |
| Female sex, n (%) | 20 (91%) | 26 (93%) | 0.80 | 10 (42%) | 75 (65%) | 0.03 |
| Race/ethnicity | ||||||
| White, n (%) | 2 (9%) | 0 | 0.19 | 20 (83%) | 101 (88%) | 0.52 |
| Hispanic, n (%) | 16 (73%) | 21 (78%) | 0.68 | 0 | 1 (1%) | 0.65 |
| Black, n (%) | 4 (40%) | 7 (60%) | 0.73 | 0 | 1 (100%) | 0.65 |
| Disease duration, years | 5 (3–10) | 2.5 (0.5–8) | 0.28 | 7 (4–14) | 9 (4–16) | 0.70 |
| SLEDAI-2K | 3 (0–10) | 6 (2–12) | 0.09 | – | – | – |
| Lupus nephritis, n (%) | 12 (54%) | 10 (36%) | 0.18 | – | – | – |
| APS, n (%) | 1 (4%) | 2(7%) | 1.0 | – | – | – |
| DAS28 | – | – | – | 3.4±0.9 | 3.7±1 | 0.44 |
| CRP, mg/L | 10.5 (1.3–42.5)* | 3.0 (0.6–24.8)† | 0.22 | 2.2 (1.1–7.5) | 2.1 (1–5.7) | 0.93 |
| IL-6, pg/mL | – | – | – | 3.1 (1.8–7) | 3.6 (1.5–7.7) | 0.87 |
| Antimalarials, n (%) | 17 (77%) | 12 (54%) | 0.08 | 5 (21%) | 18 (16%) | 0.54 |
| MMF, n (%) | 11 (50%) | 10 (36%) | 0.31 | – | – | – |
| AZA, n (%) | 2 (9%) | 3 (11%) | 1.0 | – | – | – |
| Non-biologic DMARD, n (%) | – | – | – | 22 (92%) | 95 (83%) | 0.53 |
| Biologic DMARD, n (%) | – | – | – | 8 (33%) | 58 (51%) | 0.12 |
| Glucocorticoids, n (%) | 11 (50%) | 16 (57%) | 0.61 | 9 (37%) | 41 (36%) | 0.86 |
| ds-DNA, antibody, n (%) | 18 (82%) | 23 (82%) | 1.0 | – | – | – |
| SSA/anti-Ro, n (%) | 11 (50%) | 17 (61%) | 0.73 | – | – | – |
| SSB/anti-La, n (%) | 5 (23%) | 11 (39%) | 0.31 | – | – | – |
| Sm antibody, n (%) | 10 (21%) | 14 (50%) | 0.87 | – | – | – |
| RNP antibody, n (%) | 12 (54%) | 17 (61%) | 0.68 | – | – | – |
| RF>40 units, n (%) | – | – | – | 16 (67%) | 69 (60%) | 0.54 |
| Anti-CCP>60 units, n (%) | – | – | – | 14 (58%) | 80 (70%) | 0.26 |
| Hypertension, n (%) | 9 (41%) | 9 (32%) | 0.56 | 10 (42%) | 46 (40%) | 0.88 |
| Diabetes, n (%) | 2 (9%) | 1 (4%) | 0.57 | 2 (8%) | 8 (7%) | 0.68 |
| Current smoking, n (%) | 7 (32%) | 5 (18%) | 0.25 | 2 (8%) | 11 (10%) | 1.0 |
| Aspirin, n (%) | 3 (14%) | 5 (18%) | 1.0 | 6 (25%) | 38 (33%) | 0.44 |
| Statin, n (%) | 3 (14%) | 2 (7%) | 0.64 | 6 (25%) | 17 (15%) | 0.22 |
| QT-modifying medication, n (%) | 6 (27%) | 10 (36%) | 0.52 | 3 (12%) | 21 (18%) | 0.77 |
| QTc, ms | 465±48 | 469±34 | 0.73 | 452±37 | 442±32 | 0.21 |
Characteristics are expressed as n (%), as the mean±SD or as the median (IQR).
*Moderate–severe disease activity is defined as SLEDAI-2K >6 or DAS28 CRP >3.2. n=18.
†n=22.
Anti-CCP, anticitrullinated cyclic peptide; APS, antiphospholipid antibody syndrome; AZA, azathioprine; CRP, C reactive protein; DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drug; IL-6, interleukin 6; MMF, mycophenolate mofetil; QTc, corrected QT-interval; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.